Skip to main content

Advertisement

Table 1 Characteristic of the included studies in this meta-analysis

From: Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis

Study Location Study design Sample size (n) Sex (M/F) (n) Age (yrs) HBeAg (+/-) (n) Regimen Therapy period Baseline ALT (U/L) HBV DNA level (Copies/mL) Detection limit of HBV DNA
    LAM+ADV ETV LAM+ADV ETV LAM + ADV ETV LAM+ADV ETV LAM+ADV ETV LAM+ADV LAM+ADV ETV LAM+ADV ETV  
Yu [22] China Cohort 54 50 47/7 44/6 35.8±8.6 37.3±9.5 36/18 36/14 LAM 100 mg/d + ADV 10 mg/d 0.5 mg/d 96 week 175.2 ± 123.0 144.5±106.8 6.2±1.3log10 6.0±1.7log10 <300 Copies/mL
Wang [21] China Cohort 31 40 28/3 34/6 31 ± 6.78 29.8 ± 6.0 11/20 15/25 LAM 100 mg/d + ADV 10 mg/d 0.5 mg/d 48 week 165.58 ± 80.58 140.68 ± 67.68 1.42*10^6 9.04*10^5 <10^3 Copies/mL
Wei [25] China Cohort 20 22 14/6 14/8 35 ± 6.89 37 ± 6.75 20/0 22/0 LAM 100 mg/d + ADV 10 mg/d 0.5 mg/d 104 week NA NA NA NA 5*10^2 Copies/mL
Zhang [24] China RCTS 35 35 NA NA 43 ± 9 43 ± 9 +:35% +:23% LAM 100 mg/d + ADV 10 mg/d 0.5 mg/d 96 week 242 ± 112 249 ± 100 8.0±0.6log10 8.1±0.6log10 <10^3 Copies/mL
Jayakumar [23] India Cohort 21 20 M:19% M:16% 38.86±12.08 42.15±17.11 10/11 15/5 LAM 100 mg/d+ADV 10 mg/d 0.5 mg/d 24 week 53 (29–163) 44 (17–151) 5.71 (4.2-9.5)log10 7.69 (4.0-8.5)log10 <400 Copies/mL
  1. NA: not available; LAM: lamivudine; ADV: adefovir; ETV: entecavir; RCTs: randomized controlled trials